Rhumbline Advisers Has $3.20 Million Stake in Owens & Minor, Inc. (NYSE:OMI)

Rhumbline Advisers trimmed its position in shares of Owens & Minor, Inc. (NYSE:OMI) by 2.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 237,071 shares of the company’s stock after selling 7,002 shares during the quarter. Rhumbline Advisers owned 0.31% of Owens & Minor worth $3,200,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of OMI. Norges Bank acquired a new position in shares of Owens & Minor during the fourth quarter worth approximately $9,160,000. Dimensional Fund Advisors LP raised its position in shares of Owens & Minor by 8.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,210,991 shares of the company’s stock worth $81,148,000 after purchasing an additional 327,002 shares during the period. Lord Abbett & CO. LLC acquired a new position in shares of Owens & Minor during the first quarter worth approximately $4,683,000. Vanguard Group Inc. raised its position in shares of Owens & Minor by 1.9% during the first quarter. Vanguard Group Inc. now owns 8,749,866 shares of the company’s stock worth $242,459,000 after purchasing an additional 162,182 shares during the period. Finally, Kennedy Capital Management LLC raised its position in shares of Owens & Minor by 42.6% during the first quarter. Kennedy Capital Management LLC now owns 525,849 shares of the company’s stock worth $14,571,000 after purchasing an additional 157,038 shares during the period. 98.04% of the stock is owned by institutional investors and hedge funds.

Owens & Minor Trading Down 1.1 %

Shares of Owens & Minor stock opened at $15.87 on Wednesday. Owens & Minor, Inc. has a 1 year low of $12.36 and a 1 year high of $28.35. The firm has a market cap of $1.21 billion, a PE ratio of -31.12, a P/E/G ratio of 0.47 and a beta of 0.39. The stock has a fifty day moving average price of $15.30 and a 200-day moving average price of $19.07. The company has a debt-to-equity ratio of 2.17, a current ratio of 1.09 and a quick ratio of 0.51.

Owens & Minor (NYSE:OMI) last announced its earnings results on Friday, August 2nd. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.03. The firm had revenue of $2.67 billion during the quarter, compared to analyst estimates of $2.65 billion. Owens & Minor had a positive return on equity of 14.66% and a negative net margin of 0.40%. The business’s revenue was up 4.2% compared to the same quarter last year. During the same period last year, the firm posted $0.18 EPS. Equities research analysts anticipate that Owens & Minor, Inc. will post 1.57 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on OMI. StockNews.com lowered Owens & Minor from a “buy” rating to a “hold” rating in a research report on Monday, August 26th. JPMorgan Chase & Co. lowered their price target on Owens & Minor from $22.00 to $18.00 and set an “underweight” rating for the company in a research report on Wednesday, August 21st. Bank of America lowered their price target on Owens & Minor from $18.00 to $16.00 and set an “underperform” rating for the company in a research report on Tuesday, June 25th. Barclays lowered their price target on Owens & Minor from $23.00 to $18.00 and set an “equal weight” rating for the company in a research report on Monday, August 5th. Finally, Citigroup raised Owens & Minor from a “neutral” rating to a “buy” rating and lowered their price target for the company from $24.00 to $19.00 in a research report on Friday, July 19th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $20.00.

About Owens & Minor

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.